Literature DB >> 15504888

Pharmacokinetics of indinavir at 800, 600, and 400 milligrams administered with ritonavir at 100 milligrams and efavirenz in ethnic chinese patients infected with human immunodeficiency virus.

Lawrence S Lee1, Anushia Panchalingam, Marline C Yap, Nicholas I Paton.   

Abstract

We assessed the pharmacokinetics of three different doses of indinavir in five patients. All doses achieved trough concentrations above efficacy thresholds. Toxic trough concentrations were observed in all patients receiving 800 mg, in two patients receiving 600 mg, and in none receiving 400 mg. Indinavir at 400 mg may be efficacious and less toxic in patients taking ritonavir and efavirenz.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15504888      PMCID: PMC525429          DOI: 10.1128/AAC.48.11.4476-4478.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals.

Authors:  R P van Heeswijk; A I Veldkamp; R M Hoetelmans; J W Mulder; G Schreij; A Hsu; J M Lange; J H Beijnen; P L Meenhorst
Journal:  AIDS       Date:  1999-10-01       Impact factor: 4.177

Review 2.  Low-dose ritonavir for protease inhibitor pharmacokinetic enhancement.

Authors:  R Chris Rathbun; Deanna R Rossi
Journal:  Ann Pharmacother       Date:  2002-04       Impact factor: 3.154

3.  The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers.

Authors:  Rob E Aarnoutse; Karin J T Grintjes; Denise S C Telgt; Michael Stek; Patricia W H Hugen; Peter Reiss; Peter P Koopmans; Yechiel A Hekster; David M Burger
Journal:  Clin Pharmacol Ther       Date:  2002-01       Impact factor: 6.875

4.  High indinavir Cmin is associated with higher toxicity in patients on indinavir-ritonavir 800/100 mg twice-daily regimen.

Authors:  Caroline Solas; Stéphanie Basso; Isabelle Poizot-Martin; Isabelle Ravaux; Hervé Gallais; Jean-Albert Gastaut; Alain Durand; Bruno Lacarelle
Journal:  J Acquir Immune Defic Syndr       Date:  2002-04-01       Impact factor: 3.731

5.  Therapy with efavirenz plus indinavir in patients with extensive prior nucleoside reverse-transcriptase inhibitor experience: a randomized, double-blind, placebo-controlled trial.

Authors:  D W Haas; W J Fessel; R A Delapenha; H Kessler; D Seekins; M Kaplan; N M Ruiz; L M Ploughman; D F Labriola; D J Manion
Journal:  J Infect Dis       Date:  2000-12-29       Impact factor: 5.226

6.  Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy.

Authors:  J H Condra; C J Petropoulos; R Ziermann; W A Schleif; M Shivaprakash; E A Emini
Journal:  J Infect Dis       Date:  2000-08-15       Impact factor: 5.226

7.  Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load.

Authors:  Juan A Arnaiz; Josep Mallolas; Daniel Podzamczer; Jan Gerstoft; Jens D Lundgren; Pedro Cahn; Gerd Fätkenheuer; Antonella D'Arminio-Monforte; Arnaldo Casiró; Peter Reiss; David M Burger; Michael Stek; José M Gatell
Journal:  AIDS       Date:  2003-04-11       Impact factor: 4.177

8.  Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients.

Authors:  David Burger; Mark Boyd; Chris Duncombe; Mariet Felderhof; Apicha Mahanontharit; Kiat Ruxrungtham; Sasiwimol Ubolyam; Michael Stek; David Cooper; Joep Lange; Praphan Phanupak; Peter Reiss
Journal:  J Antimicrob Chemother       Date:  2003-03-28       Impact factor: 5.790

9.  Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team.

Authors:  S Staszewski; J Morales-Ramirez; K T Tashima; A Rachlis; D Skiest; J Stanford; R Stryker; P Johnson; D F Labriola; D Farina; D J Manion; N M Ruiz
Journal:  N Engl J Med       Date:  1999-12-16       Impact factor: 91.245

10.  Efficacy of a twice-daily antiretroviral regimen containing 100 mg ritonavir/400 mg indinavir in HIV-infected patients.

Authors:  Jade Ghosn; Claire Lamotte; Hocine Ait-Mohand; Marc Wirden; Rachid Agher; Luminita Schneider; François Bricaire; Claudine Duvivier; Vincent Calvez; Gilles Peytavin; Christine Katlama
Journal:  AIDS       Date:  2003-01-24       Impact factor: 4.177

View more
  1 in total

1.  Pharmacokinetics of darunavir at 900 milligrams and ritonavir at 100 milligrams once daily when coadministered with efavirenz at 600 milligrams once daily in healthy volunteers.

Authors:  Gaik H Soon; Ping Shen; Eu-Leong Yong; Paul Pham; Charles Flexner; Lawrence Lee
Journal:  Antimicrob Agents Chemother       Date:  2010-04-12       Impact factor: 5.191

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.